New financing and business models to accelerate the development of novel therapeutics
Author(s)Kim, Esther S
Technology and Policy Program.
Andrew W. Lo.
MetadataShow full item record
Many obstacles contribute to the uncertainty and risk associated with early drug development, leading to the "valley of death" in which promising drug candidates experience difficulties in reaching the market. These challenges have serious consequences for patient populations facing significant unmet medical needs. In this paper, we highlight three models that offer innovative financing mechanisms or new business models for early stage biopharmaceutical assets. Specifically, we evaluate and profile examples of venture philanthropy and academic-industry partnerships as sources of financial capital for early stage assets. In addition, we identify a "one-disease" business model in biotechnology that can mitigate risk and accelerate the translation of biomedical research into novel therapeutics. The three examples highlight the potential for creative mission-driven models to speed up drug development and provide capital in the earliest, and often riskiest, stages of drug development. These models are collaborative and leverage the expertise of the various stakeholders in the process, including patient advocates, private sector drug developers, and academic researchers.
Thesis: S.M. in Technology and Policy, Massachusetts Institute of Technology, School of Engineering, Institute for Data, Systems, and Society, Technology and Policy Program, 2017.Cataloged from PDF version of thesis.Includes bibliographical references (pages 119-125).
DepartmentMassachusetts Institute of Technology. Engineering Systems Division; Massachusetts Institute of Technology. Institute for Data, Systems, and Society; Technology and Policy Program
Massachusetts Institute of Technology
Institute for Data, Systems, and Society., Engineering Systems Division., Technology and Policy Program.